Athera and Medirista Sign Agreement
News Aug 27, 2013
Athera Biotechnologies AB has announced that the rights to the recombinant Annexin A5 have been transferred to Medirista AB.
Medirista is a biotech company owned by the original innovators of the Annexin A5 project, Johan and Anna Frostegård.
The whole patent portfolio together with key preclinical assets have been transferred. Athera will continue its focus on development of the lead product candidate, the fully human antibody in atherosclerosis.
Recombinant Annexin A5 has been developed to preclinical stage by Athera as an anti-inflammatory therapy, primarily targeting prevention of complications following vascular surgery.
Annexin A5 has been shown to beneficially affect remodelling in a preclinical model of coronary bypass grafting. Another study showed that low doses of Annexin A5 could prevent injury in a model mimicking catheter-based percutaneous interventions (PCI) in mice.
Millions of PCI procedures are done per year due to acute coronary syndrome (ACS) and the number is rapidly increasing.
Working Together Helps Phage Overcome CRISPRNews
Surprising results show that phage join forces to overcome bacteria’s CRISPR -based immune defenses. Improved understanding of the interactions between phage and their bacterial hosts could help advance phage-based therapies and stimulate viral research.READ MORE
Study in Mouse Model of Autism Finds Mother's Microbiome Determines RiskNews
The microbiome is the collection of microorganisms, such as bacteria, that naturally live inside us. New research in a mouse model suggests the microbiome determines autism risk.READ MORE
DNA ‘Shield’ Discovered with Crucial Roles in Normal Cell Division, the Immune System & CancerNews
Scientists have made a major discovery about how cells repair broken strands of DNA that could have huge implications for the treatment of cancer.READ MORE